SCHEMBL12901017

SCHEMBL12901017

COc1cccc(NC(=O)c2sccc2Nc2ccnc3[nH]ccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
GRM4 Q14833 1/20 0.47
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
BRAF P15056 1/20 0.46
KDR P35968 2/20 0.46
TSHR P16473 2/20 0.45
ROCK1 Q13464 1/20 0.45
FBP1 P09467 1/20 0.45
KMT2A Q03164 2/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 2/20 0.44
TNNI3K Q59H18 1/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPK10 P53779 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TNIK Q9UKE5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12901021 0.88 MET (0.52) SMN1; SMN2NPC1RAB9AKDRTSHR
SCHEMBL1230852 0.84 ROCK1 (0.49) SMN1; SMN2CYP2D6CYP2C9ROCK1KMT2A
SCHEMBL12900654 0.83 ROCK1 (0.47) RAB9AROCK1POLB
SCHEMBL12901016 0.82 ABCB1 (0.52) KDRROCK1KMT2AALDH1A1MEN1
SCHEMBL12900698 0.82 AKT1 (0.49) ROCK1MAPK1
SCHEMBL1229818 0.82 AKT1 (0.49) ROCK1MAPK1
SCHEMBL1231765 0.81 AKT1 (0.49) ROCK1MAPK1
SCHEMBL12900696 0.81 THRB (0.46) SMN1; SMN2CYP2D6ROCK1KMT2ATNIK
SCHEMBL7993463 0.80 TNNI3K (0.60) SMN1; SMN2NPC1RAB9ATSHRROCK1
SCHEMBL12900384 0.80 KDR (0.51) SMN1; SMN2RAB9ACYP2D6CYP2C9KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC SMN1; SMN2 3720/4885NPC1 1174/4885RAB9A 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.